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Abstract 
 
Background: Aspartame (APM), a common artificial sweetener, has been used for diabetic subjects and body weight 
control for a long time. The goal of the present study was to evaluate the impact of   APM consumption on 
neurotransmitters and oxidative stress in rat’s brain.  
Materials and Methods: Four groups of male Wistar albino rats was used: Group1, control (Rats fed on normal diet). 
Group 2: Rats were received aspartame (50 mg/kg b w). Group3: Rats were received aspartame (75 mg/kg b w). Group 4: 
Rats were received aspartame (125 mg/kg b w). Five rats were decapitated after 10, 20, 30 and 40 days from start of 
experiment. Blood and brain tissue were collected for biochemical analysis. Biochemical analysis of brain tissue includes 
neurotransmitters (Acetylcholine, epinephrine, norepinephrine, γ-aminobutyric acid and serotonin). Serum for 
determination of lipid peroxidation (MDA), reduced glutathione and superoxide dismutase (SOD).  
Results: the data obtained showed that antioxidant activities (SOD and GSH) were reduced significantly (p<0.001) while 
malondialdhyde (MDA) level was increased compared with control. Brain neurotransmitters levels (serotonin, GABA and 
dopamine) were reduced significantly compared with control (p<0.001, <0.01) after consumption of APM. However, the 
level of acetylcholine and norepinephrine increased in rats fed AMP compared with control (p<0.001). The effect of APM 
is dose dependent.  
Conclusion:  Consumption of APM for a long time increased oxidative stress in brain tissue and disruption in 
neurotransmitters that affect physiological functions. 
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Introduction  
 
 Aspartame (APM) (L-aspartyl-L-phenylalanine methyl ester)  is a dipeptide, and is considered as one of the  
common  artificial sweeteners used by FDA (Weihrauch and Diehl, 2004). This sweetener gained a lot of attention due to 
its low calories while retaining sweet taste, low price and potential health effects, such as reduction in body weight and for 
the management of  diabetes (Olivier et al., 2015). APM was increasingly introduced in many food products as diet sodas, 
cereals, sugar-free desserts, dairy products and pharmaceuticals formulations (Gardner et al., 2012).After ingestion, APM is 
easily absorbed from the intestinal mucosal cell and hydrolyzed to phenylalanine, methanol and  aspartic acid  (Ranney et 
al., 1976). Consequently , high doses of aspartame consumption increased  the levels of this intermediates  in the circulation 
(Stegink, 1987).Previous study suggested that high doses of aspartame or its individual metabolites particularly methanol 
exert toxic effect  on the brain (Kruse, 1992). It was reported that methanol is primarily oxidized to formaldehyde and then 
into formate, that is involved in methanol toxicity in human. This is accompanied by production of superoxide anion and 
hydrogen peroxide (Lee et al., 1994, Eells et al., 2000, Parthasarathy et al., 2006).There are a few data showed the effect of 
aspartame consumption on specific neurological conditions such as headache, insomnia and seizures (Johns, 1986), 
alterations in regional concentrations of catecholamine which is accompanied with behavioral disturbances (Coulombe and 
Sharma, 1986, Humphries et al., 2008). The rational of this study was to investigate whether long-term uses of aspartame 
can affect oxidative stress and brain neurotransmitters in albino rats  
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Material and Methods 
Chemicals and Kits 
  
 Aspartame (L aspartyl- L-phenylalanine methyl ester) was purchased from Noga-biochem, Shandong–china. 
Biochemical parameter Kits for the determination of brain tissue was obtained from Bio-diagnostic Company, Jeddah, 
Saudi Arabia. All tools that were used in the experiment were from Shafi'i Foundation for Medical Equipment, Jeddah, 
Chemicals that used to determination of the blood was obtained from sigma-Aldrich (Gillinham, UK).  
 
Experimental animals 
 
 One hundred and sixty male albino rats, age 4 weeks and weighting 120-150 g, were obtained from the Animal 
House of King Fahd Medical Research Center (KFMRC), King Abdulaziz University (Jeddah, Saudi Arabia). Rats were 
placed in stainless cages (5 rats/cage). Rats were fed standard diet obtained from Saudi Company for oils, Jeddah. All 
animals were allowed one week to acclimatize in animal housing conditions before being used for the study. Experiments 
were conducted according to the Ethical Committee of King Abdulaziz University (Jeddah, Saudi Arabia). 
Animals were randomly divided into four groups (each 40 rats). Group I, served as control group. Rats in  groups II-IV 
were fed aspartame orally at a dose of 50, 75 and 125 mg/kg BW/day respectively for 40 days (Labra-ruiz et al., 2007).  
 
Blood and brain tissue collection 
 
 Blood and brain samples were collected after 10, 20, 30 and 40 days from the start of the experiment. At the end of 
the experiment, rats were anesthetized with thiopental and whole blood was collected and brain tissue was quickly removed 
and cleaned. Blood samples were centrifuged at 4°Cat 3000 rpm and serum was kept in Eppendorf tubes, brain was kept at 
-80°Cfor further analysis. 
 
Biochemical analysis 
Assay of acetylcholine 
 
 Acetylcholine (ACh) was determined according to Vizi et al. (1985) by Enzyme-linked Immuno-Sorbent Assay 
(ELISA) using Choline/Acetylcholine Assay Kit (Biosource International, USA) .The colorimetric assay of GABA was 
performed in presence of glutamate decarboxylase (YANG Sheng-Yuan, 2006).The serotonin level  in the brain was 
determined by fluorescence method (Anderson et al., 1992). A fluorometric method was developed for the determination of 
norepinephrine and epinephrine (Fiorica and Moses, 1971). Reduced glutathione (GSH) was determined according to Baker 
et al. (1990). SOD was determined by the  method of Beauchamp and Fridovich (1971). Plasma MDA level was measured 
by the modified method of Satoh (Kei, 1978). 
 
Statistical analysis 
 
 Statistical analysis was done by SPSS version 20, SPSS Inc., Chicago, IL, USA) was used for data analysis. A 
probability (P) <0.05 was considered significant. 
 
Results 
 
 Data presented in Table1 showed that, after 40 days of aspartame feeding, there was  a significant  increase in body 
weight at 50 or 75 mg/kg/body  (p<0.01 and <0.001) respectively compared with control, whereas non-significant changes 
in body weight at 125 mg/kg. The increase in body weight was correlated with time as compared with control group 
(p<0.001). 
 The levels of serotonin, GABA and dopamine were reduced in the brain tissue homogenate in rats given 50, 75 and 
125 mg/kg (p<0.05, P<0.001 and p<0.001) respectively compared to control. In contrast, the level of Ach at doses 50, 75, 
and 125 mg/kg was significantly higher than control group (P <0.01, P<0.001 and p<0.001) respectively, as well as of 
norepinephrine at same doses (p<0.05). The level of epinephrine in treated rats were increased only at doses 50 and 
75mg/kg AMP compared with control group (P <0.05, P<0.001 and p<0.001). The GSH levels of brain homogenate in the 
aspartame-treated rats were shown in Table 3. The results showed that there were non-significant changes at days 10, 20 
and 40 in the studied groups. Interestingly, at day 30, the glutathione levels in rat fed on aspartame 50 and 125 mg/kg/day 
were significantly lower than control (P<0.001 and p<0.001, p<0.05) respectively. The activities of SOD in different 
studied groups at different durations are shown in Table 4. It was found that at days 30 and 40, there were no significant 
changes of brain SOD compared with control. However, at day 10, rat fed on aspartame 75 mg/kg/day or 125 mg/kg/day 
were significantly higher than control (P<0.01 and p<0.001respectively). At day 20, rat fed on aspartame 50 mg/kg/day and 
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rat fed on aspartame 75 mg/kg/day were significantly higher than control (P =0.024 and P =0.023, respectively). Table 5 
showed that at days 20 and 30, there were non-significant changes in brain homogenate levels of MDA in different studied 
groups. However, at days 10, the concentrations of 75 and 125 mg/kg/day, the brain MDA levels were significantly higher 
than the controls (P =0.025 and P =0.006, respectively), and also at day 40, the brain MDA levels with concentration of 50 
and 125 mg/kg/day were significantly higher than the controls (P =0.049 and P =0.025, respectively). 
 
Table1: Initial and final body weight (g) of different groups at different times (mean± SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results were expressed as mean ± SD (p<0.05), analysis of variance for multiple comparison by  
Dennett’s test. a: Significance vs. control 
 
Table 2: The levels of neurotransmitters in brain tissue in all studied groups (mean± SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results were expressed as mean ± SD (p<0.05), analysis of variance for multiple comparison  
by Dennett’s test. a: Significance vs. control. N: number of rats  
 
125 mg/kg 75 mg/kg 50 mg/kg  Control 
 
Experimental 
  groups 
Variables 
153.3±14.92 
 
139.2±27.78 
 
123.3±24.8 
 
142.9±20.16 
 
Body weight (initial) (g) 
310±30 
 
363.3±11.54 
 
370±20 
 
326.7±25.16 Body weight (final) (g) 
125 mg  
Aspartame 
N=10 
75 mg aspartame 
N=10 
50 mg aspartame 
N=10 
Control 
N=10 
Groups 
24±3.5a 
 
20±2.5a 
 
33±8 a 
 
90±19 Serotonin ( µg /g) 
41±5a 
 
53±9a 
 
66±6 a 
 
42±3 
 
GABA (µg /g) 
39±7.5a 
 
26±11a 
 
23±1.3a 
 
11±1.5 
 
Acetylcholine (µg/g) 
 
60±16a 
 
54±19a 
 
53±13 a 
 
33±7 
 
Norepinephrine (ng /g) 
 
93±15a 
 
109±19a 
 
90±13 a 
 
18.1±2.5 
 
Epinephrine (ng /g) 
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            Table 3: Effect of AMP on brain Glutathione (mg/dl) in different studied groups at different days. 
 
  Time 
Groups 
 
10 days 
N=10 
 
20 days 
N=10 
 
30 days 
N=10 
 
40 days 
N=10 
Control 
2.61±1.27 3.44±0.50 3.31±0.13 3.19±0.29 
APM (50 mg/kg/day) 
3.58±1.30 3.24±0.34 2.26±0.52a 3.36±0,87 
APM (75 mg/kg/day) 2.84±0.96 2.61±9.12 2.66±0.49a 3.57±0.96 
APM (125 mg/kg/day) 3.06±1.72 2.88±0.76 2.28±0.13a 3.45±0.80 
Data are expressed as mean ± standard deviation. a Denotes that the data are significantly different from the control group at P< 0.05. Analysis was made using 
ONEWAY ANOVA test (LSD). N: number of rats  
 
              Table 4: Brain levels of SOD (U/L) in different studied groups at different days. 
 
Groups 10 days 
N=10 
20 days 
N=10 
30 days 
N=10 
40 days 
N=10 
Control 
2216.04±149.85 1940.19±38.72 2331.94±226.23 2283.26±550.09 
APM (50 mg/kg/day) 2515.07±104.62 2714.42±322.02a, 2496.52±12.04 2777.00±286.97a, 
     
APM (75 mg/kg/day) 
 
2946.22±383.19a, b 2719.05±261.40a, 2515.07±182.72 2603.15±74.35 
     
APM (125 mg/kg/day) 
 
2929.99±281.73a, b 2338.90±537.96 2306.44±104.39 2399.17±163.53 
     
Data are expressed as mean ± standard deviation. a Denotes that the data are significantly different from the control group at P< 0.05. b Denotes that the data are 
significantly different from APM (50mg/kg) at P < 0.05. Analysis was made using ONEWAY ANOVA test (LSD). N: number of rats  
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                 Table 5: Brain levels of MDA (nm/dl) in different studied groups at different days 
 
Groups 10 days 
 
N=10 
20 days 
N=10 
30 days 
N=10 
40 days 
N=10 
Control 20.30±7.63 28.52±5.74 26.39±4.85 25.88±12.53 
APM (50 mg/kg/day) 20.30±7.63 34.86±1.54 35.07±12.42 38.92±5.18a 
     
APM (75 mg/kg/day) 37.24±8.87a, b 41.16±4.56 32.06±5.88 33.34±1.98 
     
APM (125 mg/kg/day) 
 
43.14±5.54a, b 40.16±3.44 32.06±5.88 41.42±1.41a 
     
Data are expressed as mean ± standard deviation. aDenotes that the data are significantly different from the control group at P< 0.05. Analysis was made using 
ONEWAY ANOVA test (LSD). N: number of rats  
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Discussion 
 
 The goal of the present study was to evaluate the impact of long-term use of APM on neurotransmitter levels and 
oxidative stress in the brain of albino rats. Neurotransmitters are chemical mediators released in response to stimuli  that 
change activity in neurons, when chemical molecules pass over a synapse they attach to special receiving areas on the next 
neuron  and exert its action (Sudhof, 2013). The effects of APM on neurotransmitters ACh, serotonin, GABA, epinephrine 
(E) and norepinephrine (NE) were investigated. Results obtained showed a significant elevation in brain neurotransmitters 
ACh, norepinephrine, epinephrine and serotonin (p value<0.01, 0.001, 0.05, 0.001) respectively, compared with control.  
The AMP composed of 50% phenylalanine, 40% aspartic acid and methanol (10%). Phenylalanine is the precursors of 
catecholamines, therefore, NE and E were elevated on long term utilization. On the same time, tryptophan will not be 
adequately carried across the BBB and serotonin production will be compromised in APM administered. The NE and E 
levels in brain increased significantly.  
 Coulombe and Sharma (1986) analyzed different regions of brain  for catecholamine  and serotonin 
neurotransmitters and their major metabolites. They reported that animals given single doses of APM increased adrenergic 
chemical mediators, which were not apparent after repeated doses. However, a decreased serotonin and its metabolite (5-
hydroxyindoleacetate) was found in several regions. 
 Oxidative damage lead to endothelial abnormality by changing NO release in the circulation (Pandey and Rizvi, 
2010). Based on our results, APM treatment induced lipid peroxidation and increased levels of MDA that considered  as a 
marker of oxidative stress(Humphries et al., 2008). In this study rats injected with APM showed a significant elevation in 
the level of MDA as compared with control. MDA levels increased by increasing the dose and duration of AMP injection 
(P<0.001).  The Antioxidants potential to remove free radicals act by different mechanism as prevention, scavenger and 
repair. Preventive antioxidants attributed to stop the formation of reactive oxygen species (ROS). These include SOD that 
catalysis the dismutation of superoxide to H2O2 and catalase that breaks it down to water. Interception of free radicals is 
mainly by radical scavenging, while at the secondary level scavenging of peroxyl radicals are affected. The effectors 
include various antioxidants like vitamins C and E, glutathione, other thiol compounds, carotenoids, flavonoids, etc. At the 
repair and reconstitution level, mainly repair enzymes are involved (Sies 1996). The elevation of MDA is accompanied 
with reduction in GSH and superoxide dismutase (P<0.001 and < 0.01, respectively).  
 The reduction in glutathione level  observed in our study may be attributed to methanol release from aspartame, 
this is  due to methanol metabolism depends upon glutathione (Parthasarathy et al., 2006). The reduction  of reduced 
glutathione, elevation of  oxidized  GSSG and decrease of the reduced/oxidized ratio increase cell sensitivity to oxidative 
stress (Shelly et al., 2009). This alteration may be due to the production of free radicals by methanol intermediate of APM. 
Reduced form of glutathione  prevent  the cellular content from  attack to  the toxic effects of lipid peroxidation (Shelly et 
al., 2009). Normally, GSH can bind with superoxide and hydroxyl radical (Atasayar et al., 2009). The results obtained may 
provide evidence that APM intake enhances generation of oxidative stress in rat by altering the glutathione ratio status.  
In conclusion, long term APM consumption increased level of lipid peroxidation and reduction in antioxidant activities 
compared with control. In addition, it caused disruption in brain concentrations of catechol-amines. However, APM should 
be used under control and physician advice. 
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